BACKGROUND: Management of Graves disease includes antithyroid drugs, 131I therapy, or thyroidectomy. Our aim was to review our institutional experience with definitive treatments for Graves disease. METHODS: This was a retrospective review of patients undergoing 131I therapy (n = 295) or thyroidectomy (n = 103) for Graves disease (2003-2015). Demographic, clinical, pathology, and outcome data were collected from institutional databases. RESULTS: 131I therapy patients were older (39.1 years vs 33.4 years, P = .001). There was no difference in the presence of ophthalmopathy between groups. A larger proportion of children received thyroidectomy than 131I therapy (17.1% vs 9.2%, P = .026). The success rate of the first 131I therapy dose was 81.4%. Overall success rate, including additional doses, was 90.1%. Rapid turnover of iodine correlated with 131I therapy failure (58.3% rapid turnover failure vs 14.9% non-rapid turnover failure, P < .05). All surgical patients underwent total or near-total thyroidectomy. 131I therapy complications included worsening thyrotoxicosis (1%) and deteriorating orbitopathy (0.7%). Operative complications were higher than 131I therapy complications (P < .05) but were transient. There was no worsening orbitopathy or recurrent Graves disease among surgical patients. CONCLUSION: A higher proportion of pediatric Graves disease patients underwent thyroidectomy than 131I therapy. Rapid turnover suggested more effective initial management with operation than 131I therapy. Although transient operative complications were high, 131I therapy complications included worsening of Graves orbitopathy among those with pre-existing orbitopathy.
BACKGROUND: Management of Graves disease includes antithyroid drugs, 131I therapy, or thyroidectomy. Our aim was to review our institutional experience with definitive treatments for Graves disease. METHODS: This was a retrospective review of patients undergoing 131I therapy (n = 295) or thyroidectomy (n = 103) for Graves disease (2003-2015). Demographic, clinical, pathology, and outcome data were collected from institutional databases. RESULTS:131I therapy patients were older (39.1 years vs 33.4 years, P = .001). There was no difference in the presence of ophthalmopathy between groups. A larger proportion of children received thyroidectomy than 131I therapy (17.1% vs 9.2%, P = .026). The success rate of the first 131I therapy dose was 81.4%. Overall success rate, including additional doses, was 90.1%. Rapid turnover of iodine correlated with 131I therapy failure (58.3% rapid turnover failure vs 14.9% non-rapid turnover failure, P < .05). All surgical patients underwent total or near-total thyroidectomy. 131I therapy complications included worsening thyrotoxicosis (1%) and deteriorating orbitopathy (0.7%). Operative complications were higher than 131I therapy complications (P < .05) but were transient. There was no worsening orbitopathy or recurrent Graves disease among surgical patients. CONCLUSION: A higher proportion of pediatric Graves diseasepatients underwent thyroidectomy than 131I therapy. Rapid turnover suggested more effective initial management with operation than 131I therapy. Although transient operative complications were high, 131I therapy complications included worsening of Graves orbitopathy among those with pre-existing orbitopathy.
Authors: Shamasunder H Acharya; Alison Avenell; Sam Philip; Jennifer Burr; John S Bevan; Prakash Abraham Journal: Clin Endocrinol (Oxf) Date: 2008-04-21 Impact factor: 3.478
Authors: Vishnu Sundaresh; Juan P Brito; Zhen Wang; Larry J Prokop; Marius N Stan; Mohammad H Murad; Rebecca S Bahn Journal: J Clin Endocrinol Metab Date: 2013-07-03 Impact factor: 5.958
Authors: David F Schneider; Philip E Sonderman; Michaela F Jones; Kristin A Ojomo; Herbert Chen; Juan C Jaume; Diane F Elson; Scott B Perlman; Rebecca S Sippel Journal: Ann Surg Oncol Date: 2014-07-08 Impact factor: 5.344
Authors: Dawn M Elfenbein; David F Schneider; Jeffrey Havlena; Herbert Chen; Rebecca S Sippel Journal: Ann Surg Oncol Date: 2014-09-23 Impact factor: 5.344
Authors: Jonathon O Russell; Christopher R Razavi; Mohammad Shaear; Lena W Chen; Andrew H Lee; Rohit Ranganath; Ralph P Tufano Journal: J Clin Endocrinol Metab Date: 2019-03-12 Impact factor: 5.958
Authors: Suzanne P MacFarland; Andrew J Bauer; N Scott Adzick; Lea F Surrey; Jessica Noyes; Ken Kazahaya; Sogol Mostoufi-Moab Journal: J Clin Endocrinol Metab Date: 2018-08-01 Impact factor: 5.958
Authors: Sarah L Lutterman; Nitash Zwaveling-Soonawala; Hein J Verberne; Frederik A Verburg; A S Paul van Trotsenburg; Christiaan F Mooij Journal: Eur Thyroid J Date: 2021-07-12
Authors: Min Joo Kim; Sun Wook Cho; Ye An Kim; Hoon Sung Choi; Young Joo Park; Do Joon Park; Bo Youn Cho Journal: Endocrinol Metab (Seoul) Date: 2022-06-16